3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
157
Carcinoma, Intraductal, Noninfiltrating
16
Breast Carcinoma In Situ
12
Neoplasm Metastasis
9
Ovarian Neoplasms
7
Breast Neoplasms, Male
7
Neoplasms
4
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Glioblastoma
3
Breast Cancer Female
3
Urinary Bladder Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Obesity
2
Infertility
2
Hot Flashes
2
Fibroadenoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
ER+ Breast Cancer
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sleep Wake Disorders
1
Sexuality
1
Risk Reduction Behavior
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Primary Breast Cancer
1
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Alpelisib
2
ziprasidone
1
olaparib
1
exemestane
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
Fulvestrant
1
DNA, Ribosomal
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hyperglycemia
×
Tamoxifen
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled